A pilot study to evaluate the safety of subcutaneous alemtuzumab (MabCampath, Campath) in patients with B-cell chronic lymphocytic leukemia
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2007
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 24 Jul 2007 Status changed from recruiting to completed.
- 05 Nov 2005 New trial record.